Psoriasis: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• IL-17 12
• IL-23 6
• STAT3 0
• TNF 5
• JAK 1
• GLP-1 5
• TYK2 1
• PI3K 0
• NLRP3 0
• IL-6 0
• IL-1 0
• AKT 0
• MAPK 0
• PDE4 1
• NRF2 0
• PD-1 0
• PPAR 0
• STING 0
• mTOR 0
• TLR4 0
• AMPK 0
• ERK 0
• VEGF 0
• GIP 1
• MMP-9 0
• PD-L1 0
• COX-2 0
• HIF-1 0
• IL-4 0
• SIRT1 0
• TP53 0
• APOE 0
• CGRP 0
• IL-13 0
• KEAP1 0
• LAG-3 0
• PCSK9 0
• PKM2 0
• SGLT2 0
• TSLP 0
• AR 0
• BCL-2 0
• BDNF 0
• BRD4 0
• CD123 0
• CD19 0
• CD40 0
• CSF1R 0
• CTLA-4 0
• CTNNB1 0
• CXCR4 0
• EGFR 0
• EZH2 0
• FTO 0
• G6PD 0
• GPRC5D 0
• HDAC 0
• HMGB1 0
• HSP90 0
• IDH 0

10 of 10+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIAMS · F32

  Understanding the role of innate lymphoid cells within psoriasis relapse

  Ohio State University· Columbus, United States· US$84,580 awarded in fiscal year 2026· until Sept 2027

• NIH NIAMS · R56

  Leading Edge Propogation Mechanism of Human Keloid Scars

  University of California Riverside· Riverside, United States· US$712,693 awarded in fiscal year 2026· until Aug 2027

• NIH NINDS · RF1

  The peripheral mechanisms underlying mechanical itch

  University of Michigan at Ann Arbor· Ann Arbor, United States· US$1,397,313 awarded in fiscal year 2026· until Aug 2029

• NIH NHGRI · R44

  Cell Locker kit: A whole blood fixative chemistry kit for preserving single cell gene expression at room temperature to enable geographical reach of patient-centric at-home immune monitoring

  Imyoo Inc· Mountain View, United States· US$794,486 awarded in fiscal year 2026· until Aug 2028

• NIH NIAMS · R01

  Regulation of epidermal differentiation via delamination and oriented cell divisions

  Univ of North Carolina Chapel Hill· Chapel Hill, United States· US$469,412 awarded in fiscal year 2026· until Jun 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Synergistic Nano-Therapeutic Approach for Psoriasis: Targeting TNF-α and IL-17 Pathways via Transdermal Delivery (SKINNOVATE)

  Academisch Ziekenhuis Groningen· Groningen, Netherlands· EU contribution €232,916· until Oct 2027

• European Commission (Horizon Europe) · HORIZON-ERC

  Unmasking Non-Genetic Determinants Instructing Tumor Initiation (IGNITE)

  Fundacio Institut de Recerca Biomedica (Irb Barcelona)· Barcelona, Spain· EU contribution €1,995,000· until Sept 2030

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Positive allosteric modulators of the PD-1•PD-L1 interaction as a new mode of therapeutic intervention for autoimmune diseases: preclinical proof of concept in humanized mice (PAMinMICE)

  Vib Vzw· Zwijnaarde - Gent, Belgium· EU contribution €150,000· until Feb 2027

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Dissolving microneedle array patch-based psoriatic immunotherapy using nanoparticles (MAPiT)

  Stockholms Universitet· Stockholm, Sweden· EU contribution €222,728· until Feb 2027

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Overcoming limits for pre-clinical small volume liquid delivery into skin and inflammation quantification (Lab-In-Skin)

  Universiteit Twente· Enschede, Netherlands· EU contribution €150,000· until Dec 2026

  The disease is named only in the funder's project summary, not in the title.

10 of 197 running projects, newest first. Listed amounts together: US$117.2m + €31.3m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque Psoriasis

  NCT06380907· Zai Lab (Hong Kong), Ltd.· Updated 10 Aug 2026

  “Sponsor decision”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 28
• Mendelian Randomization Analysis 38
• CRISPR-Cas Systems 4
• Gene Expression Profiling 66
• Sequence Analysis, RNA 6
• Exome Sequencing 5
• Proteomics 24
• Metabolomics 13
• Flow Cytometry 11
• Immunohistochemistry 24
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 23
• Machine Learning 27
• Deep Learning 4
• Cohort Studies 63
• Genome-Wide Association Study 38

• Extracapsular and joint-dominant hand and wrist MRI patterns in psoriatic and rheumatoid arthritis: an exploratory case-control study.

  Front Immunol, Oct 2026

• Inverted Papilloma Presenting as Orbital Cellulitis and Dacryocystitis.

  Ophthalmic Plast Reconstr Surg, Sept 2026

• Effect of apremilast on entheseal bone damage in psoriasis patients at risk of developing psoriatic arthritis - data from the prospective, interventional EPOS study.

  Arthritis Res Ther, Aug 2026

• Exploratory MRI and Clinical Marker Analysis of Pustulotic Arthro-Osteitis Disease Activity From a Phase 3 Brodalumab Trial.

  J Dermatol, Aug 2026

• Bilateral knee lipoma arborescens mimicking persistent inflammatory arthritis in a patient with psoriatic arthritis.

  BMJ Case Rep, Jul 2026

• Whole body-MRI identifies widespread, low intensity inflammation in peripheral joints, and axial involvement in a third of patients with early, treatment-naïve, active PsA: data from the GOLMePsA clinical trial.

  Rheumatology (Oxford), Jun 2026

• Role of the S1P/S1PR axis in inflammation and structural damage in psoriatic arthritis: a cross-sectional study with clinical, biochemical and imaging correlation.

  RMD Open, Jun 2026

• Effect of apremilast on whole-body magnetic resonance imaging of peripheral and axial inflammation in patients with psoriatic arthritis.

  Ann Rheum Dis, May 2026

• Two patterns of sacroiliac joint bone marrow oedema are apparent in AxSpA determined by HLA-B27 status, body mass index or psoriasis.

  Joint Bone Spine, May 2026

• Feasibility of Ultrashort Echo Time MR Imaging for the Detection of Subclinical Achilles Enthesitis in Psoriasis and Psoriatic Arthritis.

  Magn Reson Med Sci, May 2026

See which targets of this disease your abstract mentions, and go to the people working on them.